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Making value based purchasing decisions in healthcare requires balancing data 
from several sources.  Information on effectiveness of interventions often comes 
from clinical trials, with less reliance on observational studies.  Historically, the 
opposite has been true of information on the cost of interventions.  More recently, 
providers of healthcare interventions such as drugs, devices, and disease 
management programs have begun to understand and appreciate the 
importance of costs in healthcare decision making.  Because of this, the clinical 
trials used to demonstrate effectiveness have begun to gather data on costs.  
This article describes some benefits and detriments of collecting cost data as a 
component of clinical trials, focusing specifically on the data related to 
productivity.  
 
Studies evaluating the cost of an intervention can look at a variety of different 
types of costs depending on the perspective of the study.  For an organization 
whose sole function is to pay for healthcare (e.g., Pharmacy Benefits Managers), 
the direct costs (e.g., the price of a pharmaceutical) are the only ones with 
importance.  For employers, it is essential to consider the indirect costs and, in 
particular, productivity. 
 
Productivity can be measured in a variety of ways, but it is usually reported as an 
amount of productivity lost due to a certain disease, or the amount of productivity 
loss avoided by using a specific type of intervention.  Productivity loss due to 
medical conditions can present itself in 2 ways.  The first is absenteeism, often 
measured by means of reviewing employee records of sick days or disability 
leave.   
 
The second type of productivity loss - presenteeism - is more difficult to measure.  
Presenteeism is defined as an employee being present at the work place but 
unable to perform at his or her usual level of productivity.  This type of 
productivity loss is often measured by surveying employees with certain 
conditions.  The employees are asked to report the percent of time they have lost 
from work as a result of their condition. 
 
The value of lost productivity can be calculated through either the friction cost 
approach, or the human capital approach.  The human capital approach yields 
estimates of wages lost for the time that an employee was not working.  The 
friction cost approach adds to that the cost of recruiting and training additional 
labor to replace that which was lost.  Depending on the condition and the 
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characteristics of the work environment, either of these approaches may be 
appropriate. 
 
Using clinical trials to measure changes in productivity due to a medical 
intervention has a number of benefits.  These trials are viewed as the gold 
standard for understanding the impact of medical interventions on health 
because they control for a lot of potentially confounding issues.  In these trials, 
patients are carefully controlled on one or more specific interventions, and the 
outcomes are measured prospectively.  This allows researchers to arrive at 
strong conclusions about the causes and effects observed in the trial. 
 
There are also some limitations when using clinical trials to measures 
productivity changes due to medical interventions.  First, one must recognize that 
health is only one of many factors that contribute to work productivity.  Changes 
observed during a clinical trial may not be due entirely to the intervention being 
tested.  In addition, some individuals choose their jobs, at least in part, in order to 
mitigate the limitations of that condition.  For example, a retail worker with back 
pain may choose to look for a job at a pharmacy rather than a home 
improvement store in order to lessen the likelihood of heavy lifting as a job 
requirement.  This type of decision lessens the perceived impact of a medical 
intervention on productivity from a clinical trial point of view. 
 
Interpreting studies that evaluate the impact of medical interventions on 
productivity can be difficult, but it is an essential step in understanding the effect 
of purchasing decisions on employees.  For instance, it is important to 
understand how the conditions in which the study was conducted differ from 
those at the company purchasing the medical intervention.  The type of work 
being done as well as the demographic characteristics of the workers may 
influence the estimation of wages for those workers. 
 
Although it has been demonstrated that productivity loss is one of the largest 
disease-associated costs for employers, we are still in the early stages of 
measuring productivity gains due to specific interventions.  As this important 
information becomes more available, employers should recognize its value in 
making purchasing decisions.  It is equally important that the consumers of this 
information understand the benefits and detriments of these study designs. 
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